μεεϊψιν ϊξιρδ
|
ων δϊψετδ αΰπβμιϊ: Levetrim Solution.
ξητωιν ϊψετδ ΰηψϊ? λπρε μΰιπγχρ δϊψετεϊ »
|
|
 αρμ δαψιΰεϊ
φεψϊ ξϊο
PER OS
ξιπεο
Solution (oral)
ωιξεω αϊψετδ
Levetrim Solution is indicated as:- monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. - adjunctive therapy:in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy
ξρτψ ψιωεν
150 58 33779 00
ιφψο
Trima Israel Pharmaceutical Products Maabarot Ltd, Israel
ϊεχσ ψιωιεο μϊψετδ
08/2013 - 07/2018
ηεξψ τςιμ
|
ψιλεζ / λξεϊ αιηιγϊ ξιπεο
|
Levetiracetam |
100 MG/ML |
ΰψιζδ
|
λξεϊ αΰψιζδ
|
ηιι ξγσ
|
ϊψετϊ ξψων
|
Bottle glass type iii |
x 300 ML |
ηεγωιν 24 |
λο |
|
|
|